MX2010004789A - Sistema de liberacion transdermica para hormonas y esteroides. - Google Patents
Sistema de liberacion transdermica para hormonas y esteroides.Info
- Publication number
- MX2010004789A MX2010004789A MX2010004789A MX2010004789A MX2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A MX 2010004789 A MX2010004789 A MX 2010004789A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery system
- transdermal delivery
- steroids
- hormones
- penetration enhancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Abstract
Un sistema de liberación transdérmica comprende una composición que comprende un agente farmacológico y un mejorador de la penetración, donde el mejorador de la penetración comprende polietilen glicol (PEG) de peso molecular promedio no mayor de 300.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98478707P | 2007-11-02 | 2007-11-02 | |
PCT/AU2008/001613 WO2009055859A1 (en) | 2007-11-02 | 2008-10-31 | Transdermal delivery system for hormones and steroids |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004789A true MX2010004789A (es) | 2010-07-05 |
Family
ID=40590452
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004788A MX2010004788A (es) | 2007-11-02 | 2008-10-31 | Sistema de liberacion transdermica. |
MX2010004789A MX2010004789A (es) | 2007-11-02 | 2008-10-31 | Sistema de liberacion transdermica para hormonas y esteroides. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004788A MX2010004788A (es) | 2007-11-02 | 2008-10-31 | Sistema de liberacion transdermica. |
Country Status (18)
Country | Link |
---|---|
US (5) | US20100279988A1 (es) |
EP (2) | EP2219603B1 (es) |
JP (2) | JP2011502172A (es) |
KR (2) | KR20100094495A (es) |
CN (2) | CN101888830B (es) |
AU (2) | AU2008318284B2 (es) |
BR (2) | BRPI0819245A2 (es) |
CA (2) | CA2704117C (es) |
DK (2) | DK2219603T3 (es) |
EA (2) | EA019760B1 (es) |
ES (2) | ES2494853T3 (es) |
HK (2) | HK1143091A1 (es) |
MX (2) | MX2010004788A (es) |
NZ (2) | NZ585034A (es) |
PL (2) | PL2214643T3 (es) |
PT (2) | PT2219603E (es) |
WO (2) | WO2009055860A1 (es) |
ZA (1) | ZA201003553B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR068408A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Pulverizacion de hormonas transdermicas |
AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
WO2009055860A1 (en) | 2007-11-02 | 2009-05-07 | Acrux Dds Pty Ltd | Transdermal delivery system |
JP5073124B2 (ja) * | 2010-12-07 | 2012-11-14 | 祐徳薬品工業株式会社 | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JPWO2013183407A1 (ja) * | 2012-06-05 | 2016-01-28 | 祐徳薬品工業株式会社 | ミルタザピン含有経皮吸収型貼付製剤 |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10201549B2 (en) * | 2013-06-14 | 2019-02-12 | Professional Compounding Centers Of America (Pcca) | Testosterone combined with anastrozole injection solutions |
US20150065426A1 (en) * | 2013-08-27 | 2015-03-05 | Professional Compounding Centers Of America | Testosterone Booster Transdermal Compositions |
US10064815B2 (en) * | 2014-05-05 | 2018-09-04 | Repros Therapeutics Inc. | Formulations and methods for vaginal delivery of antiprogestins |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10603272B2 (en) * | 2015-02-27 | 2020-03-31 | Kindred Biosciences, Inc. | Stimulation of appetite and treatment of anorexia in dogs and cats |
EP3284506B1 (en) | 2015-04-13 | 2021-04-28 | LG Household & Health Care Ltd. | Soluble microneedle containing ingredient for controlling release of neurotransmitters |
WO2016167545A1 (ko) * | 2015-04-13 | 2016-10-20 | 주식회사 엘지생활건강 | 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들 |
CA2986039A1 (en) * | 2015-05-18 | 2016-11-24 | Agile Therapeutics, Inc. | Contraceptive compositions and methods for improved efficacy and modulation of side effects |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10449201B2 (en) * | 2015-08-17 | 2019-10-22 | Alpha To Omega Pharmaceutical Consultants, Inc. | Transdermal and/or topical delivery system comprising clobazam |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2018031576A1 (en) * | 2016-08-08 | 2018-02-15 | Baucom Karan Y | Hormone delivery system and method |
EP3541394A1 (en) * | 2016-11-17 | 2019-09-25 | Cytoo | Skeletal muscle hypertrophy inducers |
KR102436756B1 (ko) * | 2017-01-31 | 2022-08-29 | 신신제약 주식회사 | 비스테로이드계 소염진통제와 살리실산 유도체를 포함하는 경피흡수 제제 |
CN107929268A (zh) * | 2017-12-19 | 2018-04-20 | 郑州泰丰制药有限公司 | 一种含质子泵抑制剂药物的透皮贴剂及其制备方法 |
EP3737374B1 (en) * | 2018-01-10 | 2024-04-03 | Celista Pharmaceuticals Llc | Testosterone transdermal spray with film |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
CN108703942B (zh) * | 2018-04-23 | 2021-04-06 | 中山大学 | 载有纳米材料包裹保胎药物的微针给药系统及制备方法 |
CN110947088A (zh) * | 2019-12-06 | 2020-04-03 | 广州新济薇娜生物科技有限公司 | 护眼组合贴片及其制备方法 |
KR102592892B1 (ko) | 2021-03-12 | 2023-10-23 | 충남대학교산학협력단 | 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK534178A (da) | 1977-12-16 | 1979-06-17 | Interx Research Corp | Anticholinerge midler med sektrtionshaemmende virkning |
US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
US4906475A (en) * | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
JPH01308225A (ja) * | 1988-06-03 | 1989-12-12 | Nissan Chem Ind Ltd | 外用医薬組成物 |
DE69007886T2 (de) * | 1989-07-21 | 1994-11-17 | Izhak Blank | Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung. |
US5276079A (en) * | 1991-11-15 | 1994-01-04 | Minnesota Mining And Manufacturing Company | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same |
JP3756512B2 (ja) * | 1992-09-21 | 2006-03-15 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 徐放性タンパク質製剤 |
WO1994007478A1 (en) * | 1992-10-06 | 1994-04-14 | The Upjohn Company | Topical pharmaceutical compositions |
US6916487B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of antiemetics |
US6916486B2 (en) * | 1996-02-19 | 2005-07-12 | Acrux Dds Pty Ltd | Transdermal delivery of analgesics |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US6998138B2 (en) * | 1996-02-19 | 2006-02-14 | Acrux Dds Pty. Ltd. | Topical delivery of anti-alopecia agents |
US7094422B2 (en) * | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
GB9902227D0 (en) * | 1999-02-01 | 1999-03-24 | Cipla Limited | Pharmaceutical composition for topical administration |
HUP0105336A3 (en) * | 1999-02-05 | 2004-06-28 | Cipla Ltd Mumbai | Topical spray compositions |
WO2001038329A1 (fr) * | 1999-11-24 | 2001-05-31 | Sumika Fine Chemicals Co., Ltd. | Cristaux de mirtazapine anhydre et leur procede d'obtention |
CA2396066A1 (en) * | 2000-01-19 | 2001-07-26 | Akzo Nobel N.V. | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
EP1441767A1 (en) * | 2001-11-09 | 2004-08-04 | QLT Inc. | Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment |
US20050186141A1 (en) * | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
AUPS317102A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Transdermal aerosol compositions |
US20050181032A1 (en) * | 2002-06-25 | 2005-08-18 | Acrux Dds Pty Ltd. | Metastable pharmaceutical compositions |
WO2004000263A1 (en) * | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
CA2433101A1 (en) * | 2003-06-23 | 2004-12-23 | Igor Gonda | Method of treatment of a female suffering from androgen insufficiency |
CN1882341A (zh) * | 2003-11-19 | 2006-12-20 | 艾克若克斯Dds有限公司 | 用于治疗皮肤损伤的方法和组合物 |
AU2004290464A1 (en) * | 2003-11-19 | 2005-06-02 | Acrux Dds Pty Ltd | Method and composition for treatment or prophylaxis of amyloidosis disorders |
CN102134231B (zh) | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
JP4613622B2 (ja) * | 2005-01-20 | 2011-01-19 | 住友電気工業株式会社 | 軟磁性材料および圧粉磁心 |
US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
JP2008536851A (ja) * | 2005-04-13 | 2008-09-11 | ユニメド ファーマスーティカルズ インク | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 |
AU2006247509A1 (en) * | 2005-05-18 | 2006-11-23 | The Gi Company, Inc. | Oral drug delivery system and methods of use thereof |
US8435944B2 (en) * | 2005-06-03 | 2013-05-07 | Acrux Dds Pty Ltd. | Method and composition for transdermal drug delivery |
WO2006128255A1 (en) * | 2005-06-03 | 2006-12-07 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
CN101296691B (zh) * | 2005-08-05 | 2011-07-27 | 努沃研究公司 | 透皮释药剂型 |
DK1937276T3 (da) * | 2005-10-12 | 2013-02-11 | Besins Healthcare Luxembourg | Forbedret testosterongel og fremgangsmåde til anvendelse deraf |
WO2008073684A1 (en) * | 2006-12-08 | 2008-06-19 | Lipo Chemicals Inc. | Composition for treating aging skin comprising a hydroxycinnamic acid such as p-coumaric acid |
WO2009055860A1 (en) * | 2007-11-02 | 2009-05-07 | Acrux Dds Pty Ltd | Transdermal delivery system |
JP5675175B2 (ja) * | 2009-06-23 | 2015-02-25 | 大陽日酸株式会社 | オゾン供給装置 |
-
2008
- 2008-10-31 WO PCT/AU2008/001614 patent/WO2009055860A1/en active Application Filing
- 2008-10-31 JP JP2010532376A patent/JP2011502172A/ja not_active Ceased
- 2008-10-31 EP EP08845600.9A patent/EP2219603B1/en not_active Not-in-force
- 2008-10-31 MX MX2010004788A patent/MX2010004788A/es active IP Right Grant
- 2008-10-31 CA CA2704117A patent/CA2704117C/en not_active Expired - Fee Related
- 2008-10-31 PL PL08845547T patent/PL2214643T3/pl unknown
- 2008-10-31 PT PT88456009T patent/PT2219603E/pt unknown
- 2008-10-31 CA CA2704116A patent/CA2704116A1/en not_active Abandoned
- 2008-10-31 WO PCT/AU2008/001613 patent/WO2009055859A1/en active Application Filing
- 2008-10-31 CN CN2008801187624A patent/CN101888830B/zh not_active Expired - Fee Related
- 2008-10-31 PT PT88455472T patent/PT2214643E/pt unknown
- 2008-10-31 DK DK08845600.9T patent/DK2219603T3/da active
- 2008-10-31 AU AU2008318284A patent/AU2008318284B2/en not_active Ceased
- 2008-10-31 EA EA201000746A patent/EA019760B1/ru not_active IP Right Cessation
- 2008-10-31 NZ NZ585034A patent/NZ585034A/en not_active IP Right Cessation
- 2008-10-31 EA EA201000747A patent/EA201000747A1/ru unknown
- 2008-10-31 BR BRPI0819245A patent/BRPI0819245A2/pt not_active IP Right Cessation
- 2008-10-31 CN CN2008801187639A patent/CN101883556B/zh not_active Expired - Fee Related
- 2008-10-31 KR KR1020107012099A patent/KR20100094495A/ko not_active Application Discontinuation
- 2008-10-31 ES ES08845600.9T patent/ES2494853T3/es active Active
- 2008-10-31 NZ NZ585033A patent/NZ585033A/en not_active IP Right Cessation
- 2008-10-31 PL PL08845600T patent/PL2219603T3/pl unknown
- 2008-10-31 EP EP08845547.2A patent/EP2214643B1/en not_active Not-in-force
- 2008-10-31 MX MX2010004789A patent/MX2010004789A/es active IP Right Grant
- 2008-10-31 AU AU2008318283A patent/AU2008318283B2/en not_active Ceased
- 2008-10-31 US US12/740,666 patent/US20100279988A1/en not_active Abandoned
- 2008-10-31 US US12/740,663 patent/US20100297032A1/en not_active Abandoned
- 2008-10-31 ES ES08845547.2T patent/ES2466676T3/es active Active
- 2008-10-31 JP JP2010532377A patent/JP5737942B2/ja not_active Expired - Fee Related
- 2008-10-31 BR BRPI0819235A patent/BRPI0819235A2/pt not_active IP Right Cessation
- 2008-10-31 DK DK08845547.2T patent/DK2214643T3/da active
- 2008-10-31 KR KR1020107012100A patent/KR101662186B1/ko active IP Right Grant
-
2010
- 2010-05-19 ZA ZA2010/03553A patent/ZA201003553B/en unknown
- 2010-10-15 HK HK10109772.3A patent/HK1143091A1/xx not_active IP Right Cessation
- 2010-10-15 HK HK10109771.4A patent/HK1144375A1/xx not_active IP Right Cessation
-
2013
- 2013-05-06 US US13/887,719 patent/US20130317462A1/en not_active Abandoned
- 2013-05-06 US US13/887,758 patent/US9078810B2/en not_active Expired - Fee Related
-
2015
- 2015-06-10 US US14/735,428 patent/US20160022820A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004789A (es) | Sistema de liberacion transdermica para hormonas y esteroides. | |
MX347056B (es) | Composiciones farmaceuticas. | |
MX2009010289A (es) | Composiciones para administracion nasal. | |
MX2010008945A (es) | Sistema de administracion de drogas con efecto estabilizante. | |
MX2010004366A (es) | Materiales inmiscibles en agua como vehiculos para suministro de farmacos. | |
WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
IL212113A0 (en) | Drug delivery methods, structures, and compositions for nasolacrimal system | |
IL173152A0 (en) | Transdermal hormone delivery system: compositions and methods | |
IL179835A0 (en) | Pharmaceutical compositions containing amphotericin b and delivery systems containing the same | |
EP1740242A4 (en) | AEROSOL LABELING DEVICE, METHOD AND COMPOSITIONS FOR PRESSURE SUPPORTED AIR SYSTEMS | |
NZ548716A (en) | Capillary moderator in an osmotic delivery system for preventing backflow into the active agent reservoir | |
WO2006084164A8 (en) | Gastric retention and controlled release delivery system | |
MY161620A (en) | Oral care formulations that enhance amount of soluble zinc | |
WO2008124735A3 (en) | Multi-functional polyglutamate drug carriers | |
RS53355B (en) | AEROSOL FORMULATION FOR COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASES) | |
WO2008089413A3 (en) | Urea foam | |
WO2008116004A3 (en) | Transdermal patch and method for delivery of vitamin b12 | |
UA93284C2 (uk) | Поліетиленгліколь-g-csf кон'югат | |
WO2005011617A3 (en) | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems | |
WO2005110358A3 (de) | Filmförmiges, oral zu verabreichendes arzneimittel, enthaltend estriol | |
GB2474001A (en) | Pharmaceutical compositions of somatotrophic hormones | |
WO2010045435A3 (en) | Salicylic acid composition | |
AU2003256882A8 (en) | Methods of drug delivery using sulphated chitinous polymers | |
MX2010004509A (es) | Formulaciones inyectables de accion prolongada. | |
MY151417A (en) | Direct dissolution of docetaxel in a solvent in polysorbate 80 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |